Participants will take different liquid versions of the study medicine in a single-blind format, meaning they will not know which specific version they are receiving. During the study, various liquid bases will be used to create a suspension, which is a mixture where solid particles are dispersed throughout a liquid. The experience will be assessed based on sensations such as bitterness, sweetness, sourness, saltiness, the feeling in the mouth, and any burning sensations on the tongue.

The study will include adults who have symptoms of RSV but are not in the hospital and who are considered at high risk of their illness becoming more severe. Participants will be randomly assigned to receive either S-337395 or placebo. The study will look at whether the medication can reduce the amount of virus in the body and will measure this by taking samples from the nose and throat at different times during the study. These samples will be tested using a laboratory method to count how much virus is present.

During the study, doctors will check for any unwanted effects of the medication and will monitor participants through physical examinations, laboratory tests, heart tracings, and measurements of vital signs such as blood pressure and heart rate. The study will also track how RSV symptoms change over time, including breathing problems and general symptoms like fever or body aches, and will measure how long it takes for these symptoms to go away. Blood samples will be taken to measure the levels of S-337395 in the body at different times after taking the medication. The maximum daily dose of the medication will be 600 milligrams, and treatment will last for up to 6 days.

The purpose of this research is to determine whether giving both an RSV vaccine to pregnant mothers and nirsevimab to their babies at 4 months of age works better than giving only nirsevimab to infants during RSV season. The study will track how well these approaches protect babies from developing RSV-related breathing problems during their first year of life.

Participants will be divided into two groups. In one group, pregnant mothers will receive the Abrysvo vaccine between weeks 32 and 36 of pregnancy, and their babies will later receive Beyfortus at 4 months of age. In the other group, babies will receive only Beyfortus during the RSV season. The babies’ health will be monitored throughout their first year of life to check for any breathing problems or infections.

The purpose of this study is to understand how long the protection from the vaccine lasts in transplant recipients and to evaluate the effects of giving an additional dose of the vaccine. The study will follow participants who previously received either one or two doses of the vaccine in an earlier study. These participants will receive one additional dose of the vaccine and will be monitored for up to 24 months.

During the study, researchers will collect blood samples to measure the body’s immune response to the vaccine. They will also monitor the participants’ health and record any side effects that may occur after vaccination. The study is specifically designed for transplant recipients who are taking medications to prevent organ rejection and have stable organ function.

In this study, pregnant women between 24 and 36 weeks of pregnancy may receive the vaccine during pregnancy, and their babies may receive the nirsevimab injection after birth, depending on which group they are assigned to. The study will follow the babies until they are 12 months old to see if they develop breathing infections caused by the virus. The main thing the researchers will look at is whether babies develop breathing infection symptoms along with a positive test for the virus by the time they reach 12 months of age.

Women who take part will need to be willing to follow all study requirements and complete surveys throughout the study period. The study is expected to start enrolling participants in 2025 and continue until 2029. Both mothers and their babies will be monitored during this time to collect information about any infections and the safety of the treatments used.

The study aims to understand how well the vaccine helps the body produce protective substances called neutralizing antibodies against two types of RSV (A and B) in older adults. The vaccine will be given as an injection, with participants receiving up to two doses over a period of 12 months. The vaccine contains a modified form of the virus’s protein along with substances that help boost the immune system’s response.

During the study, participants will be monitored for their immune response to the vaccine. The research team will also track any reactions at the injection site and throughout the body after vaccination. This includes following up with participants for six months after vaccination to ensure their safety and document any medical events that may occur.

The purpose of the research is to determine how nirsevimab affects the development of a baby’s own natural immune response (antibody levels) after encountering RSV. The study will involve two groups: a nirsevimab group of infants aged 0-3 months who receive the immunization, and a control group of children around 12-15 months of age who do not receive nirsevimab.

Participants will have blood samples collected at various timepoints to measure RSV-specific antibodies in their blood. These measurements will be taken before immunization and then at 2, 4, 6, and 12 months afterward to track how the immune system responds over time. Parents will also complete questionnaires about their child’s health and development throughout the study period.

The purpose of the study is to evaluate how well this vaccine works in preventing RSV infections in infants and toddlers. Participants in the study will receive two doses of the vaccine. The study will observe the effects of the vaccine over the course of the RSV season, which is the time of year when RSV infections are most common. The study will also include a group that receives a placebo to compare the results.

Throughout the study, researchers will monitor the health of the participants to ensure their safety and to gather information on how the vaccine affects the immune system. The study aims to provide valuable insights into the vaccine’s ability to prevent RSV-related illnesses, such as lower respiratory tract disease, which affects the lungs and can lead to more serious health issues. The study is expected to continue until 2026, with recruitment starting in 2024.

The purpose of the study is to evaluate the immune response, safety, and how the body reacts to these vaccines when given together compared to when they are given separately. Participants in the study will receive either both vaccines at the same time or one of the vaccines alone. The study will monitor the participants’ immune responses, which are the body’s defense mechanisms against infections, and any side effects that may occur after vaccination.

Throughout the study, participants will be observed for several months to assess the effectiveness of the vaccines in generating protective antibodies, which are proteins in the blood that help fight infections. The study will also track any side effects or adverse events, which are any unwanted effects that occur after vaccination. This information will help determine if the vaccines are safe and effective when administered together in older adults.

The purpose of the study is to see how well the Abrysvo vaccine works in reducing the risk of hospitalizations related to RSV infections. Participants in the study will receive the vaccine through an injection into the muscle. The study will follow participants over several RSV seasons to gather data on the vaccine’s effectiveness in preventing hospitalizations due to RSV-related respiratory diseases.

Throughout the study, researchers will monitor the number of hospitalizations due to RSV-related respiratory tract diseases, as well as other related health outcomes. These include hospitalizations for lower respiratory tract diseases, cardio-respiratory issues, and overall respiratory infections. The study aims to provide valuable information on the potential benefits of the Abrysvo vaccine in protecting older adults from serious RSV-related health problems.

The purpose of the study is to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults aged 18 to 49 who are at increased risk for RSV disease, compared to older adults aged 60 and above. Participants will receive the vaccine through an injection into the muscle. The study will monitor the immune response to the vaccine and any side effects that may occur.

Participants will be observed over a period of time to assess how their bodies respond to the vaccine. The study aims to ensure that the vaccine is safe and effective for people who are at higher risk of severe RSV infections, such as those with chronic health conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, or diabetes. The study will help determine if the vaccine can provide protection against RSV in these groups.

The purpose of the study is to evaluate how safe the new vaccine is and how well it triggers an immune response compared to the traditional BCG vaccine. Participants in the study will receive either the new vaccine or the conventional BCG vaccine through a small injection into the skin. The study will monitor participants over a period of time to observe any side effects and to measure the body’s immune response to the vaccines.

Throughout the study, researchers will collect information on any side effects experienced by participants and will analyze blood samples to assess the immune response. The study aims to provide valuable information on whether the new vaccine can offer additional protection against RSV while maintaining the benefits of the traditional BCG vaccine. This research is important for understanding how to better protect older adults from respiratory infections.

The purpose of the study is to evaluate how well the vaccine works and how safe it is for people aged 60 and above. Participants in the study will receive the vaccine at different times to see how their immune systems respond. Some participants will receive a single dose of the vaccine, while others will receive a revaccination dose before the RSV season. The study will monitor the immune response by measuring the levels of protective substances in the blood before and after vaccination.

Throughout the study, participants will be observed for any side effects or health changes. The study will also track any serious health events that occur after vaccination. This research aims to understand the best vaccination schedule to protect older adults from RSV infections effectively.

The purpose of the study is to assess how well MK-1654 can prevent RSV-associated medically attended lower respiratory infections in both pre-term and full-term infants. The study will involve monitoring the infants from the time they receive the treatment up to 150 days afterward. During this period, researchers will observe the infants for any signs of RSV-related infections and any side effects that may occur.

Participants in the study will include healthy infants who are either early or moderate pre-term (born between 29 to 34 weeks and 6 days of gestational age) or late pre-term or full-term (born at 35 weeks or later). The study will also track any adverse events, such as fever or rash, to ensure the safety of the treatment. The ultimate goal is to determine if MK-1654 can effectively reduce the incidence of RSV-related infections in infants, providing a potential new option for preventing this common and sometimes serious virus.

During the study, participants will take the medication in the form of a coated tablet by mouth. The study will monitor the progression of RSV infection by looking at clinical symptoms, which are the signs and feelings of illness that participants experience. The study will last for a period of time, and participants will be asked to report on their symptoms and any changes they notice. The study aims to understand how quickly symptoms of RSV improve and how the drug affects the overall health and daily activities of the participants.

The study will also look at the safety of EDP-938 by monitoring any side effects or adverse events that participants may experience. This includes checking vital signs, which are basic measures of health like heart rate and blood pressure, and conducting laboratory tests. The information gathered from this study will help determine if EDP-938 is an effective and safe treatment option for people with RSV who are at high risk for complications.

Participants in the study will be randomly assigned to receive either the study medicine, sisunatovir, or a placebo, which looks like the medicine but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medicine or the placebo. This helps ensure the results are not biased. The study will also measure the levels of sisunatovir in the blood to understand how the body processes the medicine.

The trial will involve multiple visits to the study center, where participants will receive the medicine and undergo various health checks to monitor their response to the treatment. These checks will include looking for any side effects and measuring important health indicators like heart rate and blood pressure. The study aims to gather important information that could help in the development of treatments for RSV in the future.